YU53402A - Preparat - Google Patents

Preparat

Info

Publication number
YU53402A
YU53402A YU53402A YUP53402A YU53402A YU 53402 A YU53402 A YU 53402A YU 53402 A YU53402 A YU 53402A YU P53402 A YUP53402 A YU P53402A YU 53402 A YU53402 A YU 53402A
Authority
YU
Yugoslavia
Prior art keywords
compound
ring
hydrocarbyl
composition
group
Prior art date
Application number
YU53402A
Other languages
English (en)
Inventor
Barry Victor Lloyd Potter
Michael John Reed
Walter Elger
Gudrun Roddersen
Henrich-Thomas Proske
Original Assignee
Sterix Limited
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0000792A external-priority patent/GB0000792D0/en
Priority claimed from GB0002115A external-priority patent/GB0002115D0/en
Application filed by Sterix Limited, Schering Ag. filed Critical Sterix Limited
Publication of YU53402A publication Critical patent/YU53402A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Abstract

Obezbeđen je farmaceutski preparat koji obuhvata (i) jedinjenje sa formulom (I) gde je: X je hidrokarbil prsten koji ima bar 4 atoma u prstenu; K je hidrokarbil grupa: Rs je sulfamatna grupa; (ii) opciono pomešani sa farmaceutski prihvatljivim nosačem, razređivačem, dodatkom ili ađuvantom, de je jedinjenje prisutno u količini da obezbedi doziranje ne veće od 200 Вµg/dan.[There is provided a pharmaceutical composition comprising (i) a compound of formula (I) wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rs is a sulphamate group; (ii) optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant, wherein the compound is present in an amount to provide a dosage of no greater than 200 Вµg/day.
YU53402A 2000-01-14 2001-01-11 Preparat YU53402A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0000792A GB0000792D0 (en) 2000-01-14 2000-01-14 Composition
GB0002115A GB0002115D0 (en) 2000-01-28 2000-01-28 Composition
US21873000P 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
YU53402A true YU53402A (sh) 2006-01-16

Family

ID=46149928

Family Applications (1)

Application Number Title Priority Date Filing Date
YU53402A YU53402A (sh) 2000-01-14 2001-01-11 Preparat

Country Status (2)

Country Link
US (1) US6653298B2 (sh)
YU (1) YU53402A (sh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
UA82851C2 (en) * 2002-08-28 2008-05-26 Estrogen replacement regimen in menopausal women
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3727332B2 (ja) 1991-02-26 2005-12-14 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 骨粗鬆症の治療方法
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5556847A (en) 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
US5705495A (en) 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19807791A1 (de) 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen

Also Published As

Publication number Publication date
US6653298B2 (en) 2003-11-25
US20010021707A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
YU53402A (sh) Preparat
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
LU91216I2 (en) Noxafil-posaconazole
AU7535798A (en) Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same
YU69902A (sh) Novi derivati piperazina
MXPA03005464A (es) Agentes antivirales.
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
ES8404360A1 (es) Un procedimiento para preparar compuestos de cefem.
WO2001051055A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
DE60114640D1 (en) Antithrombosemittel
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
AU5390900A (en) Potassium channel blocking agents
PT1463504E (pt) Composicoes compreendendo epotilonas e sua utilizacao para o tratamento de sindroma carcinoide
NZ332687A (en) use of 1-methyl-carbapenem derivatives as anti-helicobacter pylori agents
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
IL151163A0 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
AP2002002494A0 (en) Hygromycin derivatives.
AP9801235A0 (en) Erythromycin derivatives.
EP1769799A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
IT1302289B1 (it) Composizioni farmaceutiche ad attivita' antineoplastica